MultiCell Technologies Inc (MCET)

[TPX]

MULTICELL TECHNOLOGIES PUBLISHED PATENT: US PATENT 8,809,290

United States Patent 8,809,290
Assignee: Multicell Immunotherapeutics, Inc. (Woonsocket, RI)
Bot, et al. August 19, 2014

Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells

Abstract

The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective therapeutics into a highly effective one, associated with generation of class I-restricted cytolytic cells and IFN-.gamma., IL-2 producing T cells, further associated with protection against a highly virulent microbe or recovery from malignant tumoral process.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8809290.PN.&OS=PN/8809290&RS=PN/8809290

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

http://www.multicelltech.com/therapeutic-pipeline/published-patents/